(brand names Pantopan
in Italy; Protium
) is a proton pump inhibitor
drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease
. Initial treatment is generally of eight weeks' duration, after which another eight week course of treatment may be considered if necessary. It can be used as a maintenance therapy for long term use after initial response is obtained. This medication may affect the results of certain lab tests (e.g. false positive urine screen for tetrahydrocannabinal-THC). It is recommended you make sure laboratory personnel and your doctor know you are using this drug.
The active ingredient in PROTONIX (pantoprazole
sodium) Delayed-Release Tablets is a substituted benzimidazole
, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl] sulfinyl]-1 H -benzimidazole sesquihydrate, a compound that inhibits gastric acid secretion.
Pantoprazole is metabolized in the liver by the cytochrome P450
system. Metabolism mainly consists of demethylation
followed by sulfation
. Another metabolic pathway is oxidation by CYP3A4
. Pantoprazole metabolites are not thought to have any pharmacological significance.
Pantoprazole is relatively free of drug interactions, however it may alter the absorption of other medications that depend on the amount of acid in the stomach, such as ketoconazole
Pantoprazole was developed by Altana
and is currently marketed under the brand name Protonix
by Wyeth-Ayerst Laboratories
by Astron Lifesciences
, and as Pantoloc
by Solvay Pharma
, as Protium
in the UK, as Inipomp
in France, and as TopZole
in South Africa. It is manufactured by a joint venture company Zydus Altana Private Limited which was formed by Altana
and Cadila Healthcare
. The plant is located at Thane
It is available by prescription in delayed-release tablets.
It is also available for intravenous use.
On December 24, 2007, Teva Pharmaceutical released an AB-rated generic alternative to Protonix.
A study published in the August 12, 2008 issue of the Canadian Medical Association Journal found that those who use proton pump inhibitors for five or more years have a 1.6-fold increased risk of fracturng a hip, while those who use the drugs for 7 or more years have a 4.5 fold increased risk of fracturing a hip.